Clinical efficacy and safety of long-term anti-inflammatory therapy with azithromycin in children with primary ciliary dyskinesia
Open Access
- 24 March 2026
- journal article
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 1,p. 234-243
Abstract
Introduction. Long-term anti-inflammatory therapy with azithromycin in children with primary ciliary dyskinesia (PCD) reduces the frequency of exacerbations and improves the course of the disease, but it may be associated with the development of adverse effects. Aim . To evaluate the clinical efficacy and safety of long-term anti-inflammatory therapy with azithromycin in children with PCD. Materials and methods . The study included 99 children with PCD aged 2 to 18 years. The children were divided into groups: Group 1 (n = 32) included children who received azithromycin therapy for 1 year, Group 2 (n = 19) included children who received therapy for more than 2 years, and Group 3 (n = 48) included children who did not receive azithromycin therapy. The frequency of exacerbations, markers of inflammation (CRP, leukocytes, neutrophils), renal-hepatic profile (cholesterol, urea, creatinine, AST, ALT, alkaline phosphatase, total bilirubin, direct and indirect bilirubin), QT interval on ECG, and bacteriological cultures from the nose and throat with determination of sensitivity to azithromycin were evaluated. Results . Anti-inflammatory therapy with azithromycin significantly reduced the frequency of exacerbations: by 2.2 times in the first year (from 6.2 to 2.8 episodes/year) and by 1.6 times in treatment for more than 2 years (from 3.4 to 2.1 episodes/year) and the CRP level (p < 0.05). No deviations were observed in biochemical parameters and the QT interval (p > 0.05). However, an increase in antibiotic resistance was detected: the sensitivity of S. aureus decreased, and S. pneumoniae was completely resistant after more than 2 years of therapy. Conclusions . Long-term therapy with azithromycin is effective in children with PCD, significantly reducing the frequency of exacerbations and the activity of inflammation, with a favorable safety profile. However, it is associated with the progressive development of resistance to key respiratory pathogens, which requires a strictly individualized approach, dynamic microbiological monitoring, and a balance between benefits and risks for each child.Keywords
This publication has 44 references indexed in Scilit:
- Primary ciliary dyskinesia: Aetiology, diagnosis and clinical managementClinical Medicine, 2025
- Macrolide antibiotics (including azithromycin) for cystic fibrosisCochrane Database of Systematic Reviews, 2024
- Understanding Primary Ciliary Dyskinesia and Other CiliopathiesThe Journal of Pediatrics, 2020
- 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac DeathJACC, 2018
- Prognostic value of plasma apelin concentrations at admission in patients with ST-segment elevation acute myocardial infarctionClinical Biochemistry, 2017
- Effect of Azithromycin Maintenance Treatment on Infectious Exacerbations Among Patients With Non–Cystic Fibrosis BronchiectasisJAMA, 2013
- Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosisJournal of Cystic Fibrosis, 2010
- Macrolides as immunomodulatory medications for the therapy of chronic lung diseasesCurrent Opinion in Pharmacology, 2008
- Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cellsBiochemical and Biophysical Research Communications, 2006
- Macrolide resistance of Streptococcus pneumoniae isolated during long-term macrolide therapy: difference between erythromycin and clarithromycinJournal of Infection and Chemotherapy, 2005